Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Smith, B.D., Kaufman, M.D., Lu, W.P., Gupta, A., Leary, C.B., Wise, S.C., Rutkoski, T.J., Ahn, Y.M., Al-Ani, G., Bulfer, S.L., Caldwell, T.M., Chun, L., Ensinger, C.L., Hood, M.M., McKinley, A., Patt, W.C., Ruiz-Soto, R., Su, Y., Telikepalli, H., Town, A., Turner, B.A., Vogeti, L., Vogeti, S., Yates, K., Janku, F., Abdul Razak, A.R., Rosen, O., Heinrich, M.C., Flynn, D.L.
Cancer Cell
